These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34157885)

  • 21. Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus.
    Clements JN; Isaacs D; Hartman RE; Gambill K
    Clin Pharmacokinet; 2021 Feb; 60(2):153-163. PubMed ID: 33108617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post-hoc analysis.
    Araki E; Harashima S; Nishida T; Nakamura J
    J Diabetes Investig; 2022 Dec; 13(12):1971-1980. PubMed ID: 36222597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
    Rodbard HW; Lingvay I; Reed J; de la Rosa R; Rose L; Sugimoto D; Araki E; Chu PL; Wijayasinghe N; Norwood P
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2291-2301. PubMed ID: 29688502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice].
    Karásek D
    Vnitr Lek; 2022; 68(2):89-95. PubMed ID: 36208922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.
    Tuchscherer RM; Thompson AM; Trujillo JM
    Ann Pharmacother; 2018 Dec; 52(12):1224-1232. PubMed ID: 29932006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
    Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
    Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
    O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH
    Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GREATER COMBINED REDUCTIONS IN HbA
    Rodbard HW; Bellary S; Hramiak I; Seino Y; Silver R; Damgaard LH; Nayak G; Zacho J; Aroda VR
    Endocr Pract; 2019 Jun; 25(6):589-597. PubMed ID: 30865526
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
    Capehorn MS; Catarig AM; Furberg JK; Janez A; Price HC; Tadayon S; Vergès B; Marre M
    Diabetes Metab; 2020 Apr; 46(2):100-109. PubMed ID: 31539622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In brief: Higher-dose semaglutide (Ozempic) for type 2 diabetes.
    Med Lett Drugs Ther; 2022 May; 64(1650):79. PubMed ID: 35536124
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.
    Lingvay I; Capehorn MS; Catarig AM; Johansen P; Lawson J; Sandberg A; Shaw R; Paine A
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4593-604. PubMed ID: 32827435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
    Johansen P; Hunt B; Iyer NN; Dang-Tan T; Pollock RF
    Adv Ther; 2019 May; 36(5):1190-1199. PubMed ID: 30875029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
    JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide.
    Tham LS; Pantalone KM; Dungan K; Munir K; Tang CC; Konig M; Kwan AYM
    Diabetes Obes Metab; 2022 Feb; 24(2):302-311. PubMed ID: 34697882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
    Rodbard HW; Rosenstock J; Canani LH; Deerochanawong C; Gumprecht J; Lindberg SØ; Lingvay I; Søndergaard AL; Treppendahl MB; Montanya E;
    Diabetes Care; 2019 Dec; 42(12):2272-2281. PubMed ID: 31530666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes.
    Hedrington MS; Tsiskarishvili A; Davis SN
    Expert Opin Biol Ther; 2018 Mar; 18(3):343-351. PubMed ID: 29431519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study.
    Rajamand Ekberg N; Bodholdt U; Catarig AM; Catrina SB; Grau K; Holmberg CN; Klanger B; Knudsen ST
    Prim Care Diabetes; 2021 Oct; 15(5):871-878. PubMed ID: 34183269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.
    Overgaard RV; Lindberg SØ; Thielke D
    Diabetes Obes Metab; 2019 Jan; 21(1):43-51. PubMed ID: 30047216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
    Nauck MA; Petrie JR; Sesti G; Mannucci E; Courrèges JP; Lindegaard ML; Jensen CB; Atkin SL;
    Diabetes Care; 2016 Feb; 39(2):231-41. PubMed ID: 26358288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.
    Aroda VR; Rosenstock J; Terauchi Y; Altuntas Y; Lalic NM; Morales Villegas EC; Jeppesen OK; Christiansen E; Hertz CL; Haluzík M;
    Diabetes Care; 2019 Sep; 42(9):1724-1732. PubMed ID: 31186300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.